Protein maturation by the furin-like enzymes and resistance to anticancer treatments

Majid Khatib, PhD
Research Director (DR2)
French Institute of Health and Medical Research (Inserm)
Bordeaux, France

This conference is hosted by Nabil Seidah, PhD.

In person: 
IRCM Auditorium
110, avenue des Pins O, H2W 1R7 Montreal

About this conference
The pancreatic ductal adenocarcinoma (PDAC) has a bad prognosis with delayed diagnosis that significantly impedes the use of therapeutic resection. Similarly, colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell dissemination has taken place in the liver. A main reason for this situation is the already resistant or newly resistant tumors to all conventional current therapies. Using various in vitro and in vivo models, our main work is focusing on the re-sensitization of PDAC and CRC cells to chemotherapy, radiotherapy and/or immune checkpoint inhibitors by targeting the activity of the proprotein convertases, enzymes involved in the biological activation/maturation of various protein precursors crucial for the malignant phenotype of PDAC and CRC tumors.

To make sure you don't miss any of the IRCM conferences, sign up now for our newsletter!